Furmonertinib official instructions and medication instructions for patients

Furmonertinib (Furmonertinib) is a new oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), mainly targeting patients with EGFR Patients with T790Mmutated non-small cell lung cancer (NSCLC). The drug inhibits the activity of EGFR and blocks downstream signaling pathways, thereby inhibiting tumor cell proliferation and promoting apoptosis. Fumetinib has shown significant efficacy in patients with T790M mutation-positive NSCLC in clinical trials, and has certain advantages in tolerability and side effect management.

1. Indications, usage and dosage

Foumetinib is suitable for patients with locally advanced or metastatic NSCLC who have developed resistance after standard EGFR-TKI treatment and have detected T790M mutations. The official instructions recommend taking it orally once a day, and the usual dose is 80mg, which can be taken with food or on an empty stomach. If the patient tolerates the drug well and the blood concentration is insufficient to maintain the therapeutic effect, the dose can be adjusted under the guidance of a doctor, but usually not more than 160 mg per day. Treatment should be continued until disease progression or intolerable adverse effects occur.

2. Common adverse reactions and monitoring

Common side effects of fumetinib include rash, diarrhea, mouth ulcers, abnormal liver function, and mild fatigue. The rash is mostly on the face, upper chest or back and appears as papules or erythema. It is usually mild to moderate and can be controlled with topical skin care or oral antihistamines. The incidence of diarrhea is high, and patients should pay attention to hydration and electrolyte balance. If symptoms are obvious, antidiarrheal drugs can be used. Abnormal liver function is manifested by increased levels of ALT and AST. Therefore, liver function indicators need to be monitored regularly before and during treatment in order to adjust the dosage or take symptomatic treatment in a timely manner.

3. Precautions for Medication

While taking fumetinib, patients should avoid concurrent use with known potent CYP3A4 inducers to prevent reduction in drug efficacy. If you need to combine it with other drugs, you should inform your doctor in advance and conduct a corresponding drug interaction assessment. Pregnant and lactating women are not recommended to use fumetinib. Male patients should take effective contraceptive measures during treatment and for a period of time after stopping the drug. Patients with renal insufficiency or severe cardiovascular disease need to use it under the guidance of a doctor and strengthen monitoring during medication.

4. Patient medication management and life suggestions

Fumetinib is an oral drug. Patients should take it at regular times every day strictly in accordance with the doctor's instructions. They should not increase or decrease the dose at will or stop taking the drug on their own. For missed doses, the dose should be taken as soon as possible after discovery on the same day. However, if it is close to the next dose time, the missed dose should be skipped to avoid excessive blood concentration caused by repeated taking. A healthy lifestyle, including a reasonable diet, moderate exercise, and good sleep, should be maintained during treatment to improve tolerance and quality of life. Patients and their families should record adverse reactions in a timely manner and provide feedback to doctors so that individualized treatment adjustments can be made.

Foumetinib, as a highly selective oral TKI targeting EGFR T790M mutation, provides a new treatment option for NSCLC patients. Its clear indications, convenient oral administration and controllable adverse reactions give it significant advantages in clinical practice. When using fumetinib, patients should strictly follow the instructions and doctor's guidance, regularly monitor relevant indicators, and combine it with life management measures to maximize the drug's efficacy, reduce the risk of adverse reactions, and achieve personalized and precise treatment.

Reference link:https://www.drugs.com